AstraZeneca Announces $50 Billion U.S. Investment Plan by 2030 Amid Tariff Concerns

Intelligent Finance APP learned that AstraZeneca (AZN.US) announced plans to invest $50 billion in the United States by 2030, becoming the latest European pharmaceutical company to accelerate its U.S. expansion due to potential import drug tariff policies.

This funding will be used for the expansion of manufacturing bases and the development of R&D systems. Kevin Hassett, Director of the U.S. National Economic Council, revealed plans to include the construction of a $4 billion chronic disease drug factory in Virginia. Hassett emphasized that with the completion of this factory, AstraZeneca's drugs sold in the U.S. market will be largely produced domestically.

This investment decision continues AstraZeneca's strategic adjustment since Trump's election. As early as November last year, the company announced a $3.5 billion investment in the United States until the end of 2026 and disclosed that it already has nearly 18,000 employees in the U.S. The company clearly stated that the newly announced $50 billion investment is a supplement to the previous plan.

Recently, European pharmaceutical giants have increased their investments in the U.S. to address tariff risks: In April, Swiss Novartis (NVS.US) announced a $23 billion infrastructure investment, while its local rival Roche Holding (ADR.US) proposed a $500 billion investment plan; French Sanofi (SNY.US) also revealed in May a plan to invest no less than $20 billion in the U.S. by 2030. AstraZeneca and Novartis are forming a new supply chain segmentation model of "U.S. production for the U.S., European R&D, and Asian manufacturing."

AstraZeneca CEO Pascal Soriot has repeatedly called on U.S. policymakers to use tariffs prudently. Earlier this spring, he suggested that tax incentives, rather than tariffs, would be more effective in attracting pharmaceutical companies to invest in localizing production.

On the current tariff policy, Soriot expressed understanding of each country's strategic need to secure the pharmaceutical supply chain: "The localization of drug production has become a national security issue, consistent with the vision promoted by the Trump administration. The tariff policy simply accelerated the layout we would have advanced anyway." According to the latest pharmaceutical tariff plan proposed by Trump, a floating tariff will be gradually implemented starting August 1st. Companies are required to complete capacity transfers within one year or may face a maximum tariff of 200%.

Notably, Soriot has recently sparked controversy in the UK. He openly criticized the British regulatory environment for affecting competitiveness, and in January this year, AstraZeneca canceled its plan to build a £450 million vaccine factory in Liverpool. Currently, the company operates 17 production sites across 12 states in the U.S. Earlier this month, there were reports that Soriot is considering moving the company's stock listing to the U.S., a move that could impact the British capital market, which has already faced a wave of corporate withdrawals in recent years.

Under Soriot's leadership, AstraZeneca's market value has grown more than twofold, securing its place in the top tier of the global oncology drug sector. It has also established significant R&D pipelines in cardiovascular, renal, and metabolic diseases. This strategic adjustment not only reflects the general trend of multinational pharmaceutical companies responding to changes in trade policies but also highlights the profound restructuring taking place in the global pharmaceutical industry landscape.